Physician profile
David E Mika
NPI 1285659623
$698.91
in general payments reported to CMS, 2019-2025
13 companies · $99.36 in 2025
The $99.36 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.44 · 2021: $250 · 2022: $23.07 · 2023: $137 · 2024: $164 · 2025: $99.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $400.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| American Orthodontics Corporation | $250.00 | 2021 | |
| Pfizer INC. | $95.72 | 2023-2025 | |
| Novo Nordisk INC | $70.75 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $49.43 | 2023-2024 | Jardiance, Emgality |
| Exact Sciences Corporation | $48.73 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.30 | 2022-2024 | Ofev |
| Amgen INC. | $31.25 | 2024 | Krystexxa, Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $27.93 | 2023-2024 | Breztri, Farxiga |
| Scilex Pharmaceuticals INC. | $25.91 | 2023 | Ztlido |
| Otsuka America Pharmaceutical, INC. | $16.32 | 2025 | Rexulti |
| Verona Pharma, INC. | $16.13 | 2025 | Ohtuvayre |
| Janssen Pharmaceuticals, INC | $12.77 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mika listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.